EU Decision for Translarna Has Positive Read Through for Sarepta (SRPT) - Credit Suisse

November 14, 2016 6:28 AM EST
Get Alerts SRPT Hot Sheet
Price: $34.49 +1.71%

Rating Summary:
    16 Buy, 9 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 21 | Down: 18 | New: 19
Trade SRPT Now!
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

Credit Suisse analyst Alethia Young said the CHMP decision to leave PTC's DMD drug Translarna with conditional approval on market in Europe is a positive read-through for Sarepta's (NASDAQ: SRPT) potential filing in the EU.

"At 100% probability of success, EU sales are worth $26/sh to our valuation", the analyst said.

The analyst maintained an Outperform rating and price target of $41 on SRPT.

For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.

Shares of Sarepta Therapeutic closed at $39.52 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, FDA

Related Entities

Credit Suisse

Add Your Comment